ReWalk Robotics Ltd. to Host Call to Discuss Medicare Proposal to Establish Personal Exoskeletons Within a Benefit Category for Eligible Beneficiaries
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 05, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or "the Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced that it will host a conference call and webcast on Tuesday, July 11, 2023 to discuss the recent proposal from the Centers for Medicare & Medicaid Services ("CMS") to include personal exoskeletons in the Medicare benefit category for braces as part of the Calendar Year 2024 Home Health Prospective Payment System Proposed Rule, CMS-1780-P ("Proposed Rule"), released on June 30, 2023.
The Proposed Rule would establish a regulatory definition of "brace" and specify that exoskeletons like the ReWalk Personal Exoskeleton fit in this definition. Once finalized, the Medicare benefit category for personal exoskeletons would be clear – i.e., the Medicare benefit category for "leg, arm, back, and neck braces" – and payment would be on a lump sum basis. The Proposed Rule has a 60-day comment period ending on Tuesday, August 29 at 5 pm EDT. During the comment period, interested stakeholders can submit comments and feedback on the proposal prior to its expected finalization in early November.
Additional information on the Proposed Rule can be found at https://www.federalregister.gov/public-inspection/2023-14044/medicare-program-calendar-year-2024-home-health-prospective-payment-system-rate-update-home-health, as well as in the Company's corresponding press release, issued June 30, 2023, at https://ir.rewalk.com/news-releases/news-release-details/rewalk-robotics-applauds-medicare-proposal-include-personal.
Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast on July 11th at 8:30 a.m. EDT to discuss the potential impact of the Proposed Rule. They will be joined on the call by Jeannine Lynch, Vice President of Strategy and Market Access, and Ashley Barnes, exoskeleton advocate and ReWalk Personal Exoskeleton user since 2015.
To access the call, analysts and investors may utilize the following:
| Toll free (U.S.): International (U.S): Israel: Access Code: | 1-833-316-0561 1-412-317-0690 1-809-212373 Please reference the "ReWalk Robotics Ltd. Call" |
The conference call will be webcast live and the webcast can be accessed through a link on the Company's website at rewalk.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/3dupfmju. An archived webcast will also be available on the Company's website.
About ReWalk Robotics Ltd.:
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk's mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance, statements regarding the Proposed Rule and its contents, which are preliminary and subject to further review and revision by CMS prior to publication, the timing for publication and effectiveness of the final rule, and the potential business or regulatory impact of the final rule once published and effective, and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk's periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Forms 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
ReWalk Media Relations:
John Tomlin
E: [email protected]
ReWalk Investor Contact:
Mike Lawless
Chief Financial Officer
ReWalk Robotics Ltd
E: [email protected]
